NCT05774704 Curcumin and Retinal Study
| NCT ID | NCT05774704 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Texas Tech University Health Sciences Center |
| Condition | Bioavailability |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-08-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2023-08-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.
Eligibility Criteria
Inclusion: * Both male and female, age 40 - 89 years. * Diagnosed with Aβ deposits in retina (peripheral superior quadrants)--to be confirmed after consent obtained. If there is documentation the potential participant has been diagnosed with Aβ deposits in retina within 6 months before the consent session, we will use this diagnosis/documentation for eligibility criteria. Otherwise, the ophthalmic exam will be repeated after consent is obtained for the study. * No pre-existing liver or kidney diseases by self-report. Exclusion: * Patients with ocular diseases (macular degeneration, severe diabetes retinopathy) * Had used systemic antibiotics within 1 month prior to the start of the study intervention * Had taken any turmeric or curcumin products within 2 weeks prior to the start of the study intervention * Had a known allergy to black pepper * Women that are pregnant or breastfeeding
Contact & Investigator
Chwan-Li (Leslie) Shen, PhD
PRINCIPAL INVESTIGATOR
Texas Tech University Health Sciences Center
Frequently Asked Questions
Who can join the NCT05774704 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 89 Years, studying Bioavailability. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05774704 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05774704 currently recruiting?
Yes, NCT05774704 is actively recruiting participants. Contact the research team at leslie.shen@ttuhsc.edu for enrollment information.
Where is the NCT05774704 trial being conducted?
This trial is being conducted at Lubbock, United States.
Who is sponsoring the NCT05774704 clinical trial?
NCT05774704 is sponsored by Texas Tech University Health Sciences Center. The principal investigator is Chwan-Li (Leslie) Shen, PhD at Texas Tech University Health Sciences Center. The trial plans to enroll 60 participants.